

Alexion Pharmaceuticals (USA): Merger with Synageva BioPharma (USA) Changes in FTSE RAFI™ Index Series

22 June 2015

Subject to the completion of the merger with Alexion Pharmaceuticals Inc. (USA, constituent) and Synageva BioPharma Corp. (USA, constituent), FTSE announces the following changes:

Index	Change	Effective From Start of Trading
FTSE RAFI All World 3000 Index	Alexion Pharmaceuticals Inc. (USA, 2036070) will remain in the index.	25 June 2015
FTSE RAFI All World 3000 Index - QSR	Alexion Pharmaceuticals Inc. will remain in the index.	25 June 2015
FTSE RAFI US 1000 Index	Alexion Pharmaceuticals Inc. will remain in the index.	25 June 2015
FTSE RAFI US 1000 Index - QSR	Alexion Pharmaceuticals Inc. will remain in the index.	25 June 2015
FTSE RAFI US 1500 Mid Small Index	Synageva BioPharma (USA, B5VY9M0) will be deleted from the index.	25 June 2015
FTSE RAFI US 1500 Mid Small Index - QSR	Synageva BioPharma will be deleted from the index.	25 June 2015

For further information or general enquiries please contact us at info@ftse.com or call:

Client Services in UK:	Tel: +44 (0) 20 7866 1810
Client Services in EMEA:	Tel: +44 (0) 20 7866 1810
Client Services in US:	New York: (Domestic) + 1 888 747 FTSE (3873) / (International): +1 212 314 1139
Client Services in Asia Pacific:	Hong Kong: + 852 2164 3333 Australia: (Domestic Toll-Free) + 1800 653 680 / (International) + 61 (2) 9293 2864 Japan + 81 (3) 3581 2764

Alternatively please visit our website at www.ftse.com

[Terms of Use](#) | Copyright © FTSE